Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renalit Combi Colic is a standardized phytotherapeutic dietary supplement developed by Bio-Stilogit Pharmaceuticals. Formulated as an oral syrup, it contains a synergistic combination of natural plant extracts, including boldo (Peumus boldus) titrated in dimethoxy-dihydroxy-aporfine, bearberry (Arctostaphylos uva-ursi) titrated in arbutin, herniaria (Herniaria hirsuta), and asparagus (Asparagus officinalis). It is designed to support the drainage of body fluids, promote the physiological functionality of the urinary tract, and assist in the prevention and management of urinary lithiasis (kidney stones) and renal colic. Additionally, it has been clinically evaluated as an adjunct prophylaxis to limit biofilm formation and encrustation on ureteral stents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Renalit Combi Colic.